Peptide therapy TikTok claims: what the science actually supports

What did @modernwellnessclinic actually say?

The creator is promoting tesamorelin, a prescription peptide, applied as "two pumps every day, each side" to the belly. The central promise: it "incinerates and targets belly fat only" and will have you "looking good for summer." The pitch closes with a call to click a bio link and start a "fat burning program." That's the whole argument. No diagnosis context, no safety caveats, no mention that this is a prescription drug with a specific approved indication. Just summer abs.

To be clear about the mechanics being implied here: the creator is describing what sounds like a topical tesamorelin product applied directly to the abdomen, which is not how tesamorelin is administered clinically. FDA-approved tesamorelin (Egrifta) is a subcutaneous injection. If this is a compounded topical, that's a very different product with no established equivalence to the injectable form.

Does the science back this up?

Tesamorelin does have real, peer-reviewed evidence behind it for visceral fat reduction, but the population studied and the claims made here are worlds apart. The evidence is real but narrow, and this video blows past those boundaries without hesitation.

Tesamorelin is a growth hormone-releasing factor analogue. It works by stimulating the pituitary to release more growth hormone, which in turn promotes lipolysis, particularly of visceral adipose tissue. The key clinical trial was Stanley et al. (2012, New England Journal of Medicine), which showed statistically significant reductions in visceral adipose tissue in HIV-infected patients with lipodystrophy. That's the approved use: HIV-associated lipodystrophy. Not general weight loss. Not stubborn belly fat in otherwise healthy people. And critically, not via a topical pump.

A follow-up study by Falutz et al. (2010, JAMA) confirmed the visceral fat reduction finding in a similar population, with effects that partially reversed after discontinuation. There is some off-label interest in tesamorelin for metabolic syndrome and age-related visceral adiposity, but robust controlled trial data in general populations remains limited.

What did they get wrong (or right)?

Let's give credit where it's due: tesamorelin does preferentially reduce visceral fat, not subcutaneous fat. That part has scientific support. The "targets belly fat" framing, while oversimplified, is not entirely fabricated. Visceral adipose tissue does respond more than subcutaneous fat in the clinical data.

But almost everything else in this video is wrong or unverifiable. "Incinerates" is marketing language with no clinical meaning. The idea that it works as a topical pump is unsupported by any published pharmacokinetic data for tesamorelin delivered transdermally. Tesamorelin is a 44-amino acid peptide. Peptides of that size do not reliably penetrate skin barriers without specialized delivery systems, and even then, bioavailability data for compounded topical tesamorelin does not exist in peer-reviewed literature. Claiming topical application produces the same visceral fat results as studied injectable doses is, at minimum, speculative and potentially misleading consumers about what they're buying.

The "fat burning program" framing also treats a prescription peptide like a supplement. Tesamorelin is not an over-the-counter product. Its use outside of supervised clinical care raises real safety questions around IGF-1 elevation, fluid retention, and glucose metabolism effects documented in the clinical trials.

What should you actually know?

If you've seen tesamorelin promoted for general fat loss, here's what the evidence actually supports and what it doesn't. Tesamorelin has a legitimate, FDA-approved role in one specific condition. Everything beyond that is off-label territory, and off-label doesn't mean ineffective, but it does mean less evidence and more risk.

The delivery method matters enormously. Injectable tesamorelin has pharmacokinetic data. Compounded topical tesamorelin does not, at least not in any published form that would let a clinician confidently dose it. If a provider is prescribing you a tesamorelin topical without discussing this distinction, that's a conversation worth having.

Known side effects from the clinical trials include injection site reactions, peripheral edema, arthralgia, and potential effects on glucose tolerance. Anyone with a history of diabetes or pre-diabetes should be particularly cautious. These risks exist even when using it correctly. A TikTok bio link is not a substitute for that clinical conversation.

• Tesamorelin is FDA-approved only for HIV-associated lipodystrophy.
• Evidence for visceral fat reduction in general populations is limited and not from large controlled trials.
• Topical peptide delivery for a 44-amino acid molecule is pharmacologically unproven in peer-reviewed literature.
• Off-label use should happen under direct clinical supervision with monitoring of IGF-1 and glucose levels.
• No peptide "incinerates" fat. Lipolysis is a metabolic process, not a chemical burn.